IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 Read more about Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Read more about Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 Read more about Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) Read more about Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor Read more about Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings Read more about Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults Read more about Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Pagination First page « First Previous page ‹ Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 Read more about Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Read more about Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 Read more about Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) Read more about Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor Read more about Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings Read more about Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults Read more about Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants